MF
According to a study of 1,054 patients with primary MF, approximately 90% had this at time of diagnosis
What is an Enlarged Spleen?
This MPN Expert stated "For me, even 45.1% isn't good enough and any hematocrit level above 45% needs action"
Who is Claire Harrison, DM
Signs and Symptoms of this disease can be subtle and can manifest in skin/Nails/Hair, Joints/Fascia, Eyes, Lungs, Mouth, GI Tract, Genitals
What is Chronic GVHD
True/False: You may join your MSL for an introductory Call
What is True?
Incyte Motto and new color added to color palette
What is "Solve On" and lavender purple?
The primary endpoint of this study was the proportion of patients achieving a >35% reduction in spleen volume from baseline at week 24 as measured by CT or MRI
What is Comfort-I ?
Additional analysis from the CYTO-PV study found white blood cell counts greater than this number increased the risk of thrombosis
What is > 11,000
Recommended starting dose of Jakafi for Chronic GVHD
What is 10 mg orally BID?
( Acute GVHD 5 mg orally BID. Consider increasing to 10 mg BID after 3 days if ANC and platelet counts are not decreased by >50% rive to 1st day dose)
The 2nd and 4th Friday of the month at 12PM EST
What are compliance office hours?
Incyte's Head of US Oncology, Barry's successor
Who is Mohamed Issa?
In the Comfort studies, larger baseline spleen volume in MF Patients was associated with this, irrespective of treatment.
What is incremental increases in the risk of death?
In the phase 3 trial, 23% of PV patients receiving Jakafi achieved the Composite Primary Endpoint of HCT Control and 35% spleen volume reduction vs <1% of patients receiving BAT
What is RESPONSE trial?
This study was a randomized, Open-Label, Multicenter, Phase 2 Study of Jakafi vs BAT in Patients with Steroid-Refractory cGVHD. Primary Endpoint was ORR at Week 24
What is Reach3 ?
Anything above this amount CANNOT be charged on the corporate MasterCard.
What is $10,000?
Empowerment, Development, Growth, and Engagement
What is EDGE Committee acronym?
This study enrolled 2233 patients, and assessed Jakafi safety and tolerability by the frequency, duration and severity of adverse events. Additional endpoints included the proportion of patients with >50% reduction in palpable spleen length.
What is JUMP?
He was the lead MPN Expert for the Incyte sponsored MPN White Paper "Practice Perspectives Survey for PV"
Who is Dr. Rampal?
This GVHD Expert states "Seeing that Jakafi is effective across the board regardless of the organs involve gives us the confidence to initiate Jakafi at early changes in skin disease to really get the opportunity to help control cGVHD"
who is Preet Chaudhary, MD, PhD?
Meal cost limit IN OFFICE for Breakfast/Lunch/Dinner.
What is $30.00?
Incyte Mascot
Who is Sam the Squirrel?
Comfort-II 5-Year Overall Survival Probability analysis in the Jakafi Arm
What is 56% (44% for BAT)
This open-label, phase 2, randomized, controlled trial of Jakafi vs BAT was conducted in patients with high-risk PV meeting criteria for being resistant/intolerant to HU. There was no cross-over of BAT patients to Jakafi.
What is MAJIC-PV Study
The most common nonhematologic adverse reactions in the REACH Studies.
What are infections ?
aGVHD >50%
cGVHD >20%
Snacks are provided to 15 people or less, the total cost of the snacks does not exceed $7.00/person and a total cost of $105, and there are no HCP covered recipients.
What is NO signatures required ?
Name of the Incyte Band
Who is Incyte the Night?